Roscovitine-Derived, Dual-Specificity Inhibitors of Cyclin-Dependent Kinases and Casein Kinases 1
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Cyclin-dependent kinases (CDKs) and casein kinases 1 (CK1) are involved in the two key molecular features of Alzheimer's disease, production of amyloid-beta peptides (extracellular plaques) and hyper-phosphorylation of Tau (intracellular neurofibrillary tangles). A series of 2,6,9-trisubstituted purines, structurally related to the CDK inhibitor roscovitine, have been synthesized. They mainly differ by the substituent on the C-6 position. These compounds were screened for kinase inhibitory activities and antiproliferative effects. Several biaryl derivatives displayed potent inhibition of both CDKs and CK1. In particular, derivative 13a was a potent inhibitor of CDK1/cyclin B (IC 50: 220 nM), CDK5/p25 (IC 50: 80 nM), and CK1 (IC 50: 14 nM). Modeling of these molecules into the ATP-binding pocket of CK1delta provided a rationale for the increased selectivity toward this kinase. 13a was able to prevent the CK1-dependent production of amyloid-beta in a cell model. CDK/CK1 dual-specificity inhibitors may have important applications in Alzheimer's disease and cancers.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DRF05322, a CR8-related inhibitor that carries a differently linked phenylpyridine ring system (Fig. 3a, c), induced binding with two-fold lower affinity than CR8 (Extended Data Fig. 8a).”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [22]
Citations
Cites
Boys, S. F., & Bernardi, F. (1970) · Molecular Physics · doi:10.1080/00268977000101561 · Cited by 22,188
Mohamadi, F., Richards, N. G. J., Guida, W. C., Liskamp, R., Lipton, M., Caufield, C., Chang, G., Hendrickson, T., & Still, W. C. (1990) · Journal of Computational Chemistry · doi:10.1002/jcc.540110405 · Cited by 3,757
ESPript: analysis of multiple sequence alignments in PostScript.
Gouet, P., Courcelle, E., Stuart, D. I., & M√©toz, F. (1999) · Bioinformatics · doi:10.1093/bioinformatics/15.4.305 · Cited by 2,951
The selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,520
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
Self-citationGSK-3α regulates production of Alzheimer's disease amyloid-β peptides
Phiel, C. J., Wilson, C. A., Lee, V. M.-Y., & Klein, P. S. (2003) · Nature · doi:10.1038/nature01640 · Cited by 1,196
Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors
Gray, N. S., Wodicka, L., Thunnissen, A.-M. W. H., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., et al. (1998) · Science · doi:10.1126/science.281.5376.533 · Cited by 808
Self-citation
Research works printed but not linked: 6
- Manning G., 2002, Science, 298, 1933
- Meijer L., 2003, Acc. Chem. Res., 36, 417, 10.1021/ar0201198 · doi:10.1021/ar0201198
- Meijer L., 2006, CDK Inhibitors and their Potential as Antitumor Agents, 2, 187
- Menn B., 2008, Ann. Neurol.
- Rockenstein E., 2007, J. Neurosci., 27, 1981, 10.1523/JNEUROSCI.4321-06.2007 · DOI · Paper page
- Bettayeb K., 2008, Oncogene
Cited by
Tau protein kinases: Involvement in Alzheimer's disease
Martin, L., Latypova, X., Wilson, C. M., Magnaudeix, A., Perrin, M.-L., Yardin, C., & Terro, F. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2012.06.003 · Cited by 631
Circadian Timing in Cancer Treatments
Lévi, F., Okyar, A., Dulong, S., Innominato, P. F., & Clairambault, J. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094626 · Cited by 476
León, R., Garcia, A. G., & Marco‐Contelles, J. (2013) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 440
The Role of Tau in Alzheimer's Disease and Related Disorders
Medeiros, R., Baglietto‐Vargas, D., & LaFerla, F. M. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00177.x · Cited by 432
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
Słabicki, M., Kozicka, Z., Petzold, G., Li, Y.-D., Manojkumar, M., Bunker, R. D., Donovan, K. A., Sievers, Q. L., Koeppel, J., Suchyta, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2374-x · Cited by 433
Selectively Nonselective Kinase Inhibition: Striking the Right Balance
Morphy, R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901132v · Cited by 292
Meta-Selective CAr–H Nitration of Arenes through a Ru3(CO)12-Catalyzed Ortho-Metalation Strategy
Fan, Z., Ni, J., & Zhang, A. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b03402 · Cited by 285
The CK1 Family: Contribution to Cellular Stress Response and Its Role in Carcinogenesis
Knippschild, U., Krüger, M., Richter, J., Xu, P., GarcÃa-Reyes, B., Peifer, C., Halekotte, J., Bakulev, V., & Bischof, J. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00096 · Cited by 272
Roscovitine in cancer and other diseases.
Cicenas, J., Kalyan, K. P., Sorokinas, A., Stankunas, E., Levy, J., Meskinyte, I., Stankevičius, V., Kaupinis, A., & Valius, M. (2015) · PubMed · doi:10.3978/j.issn.2305-5839.2015.03.61 · Cited by 219
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
Bettayeb, K., Oumata, N., Echalier, A., Ferandin, Y., Endicott, J. A., Galons, H., & Meijer, L. (2008) · Oncogene · doi:10.1038/onc.2008.191 · Cited by 184
Self-citationProtein kinases CK1 and CK2 as new targets for neurodegenerative diseases
Perez, D. I., Gil, C., & Martinez, A. (2011) · Medicinal Research Reviews · doi:10.1002/med.20207 · Cited by 155
The DNA Damage Response in Neurons: Die by Apoptosis or Survive in a Senescence-Like State?
Fielder, E., von Zglinicki, T., & Jurk, D. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161221 · Cited by 126
Chioua, M., Samadi, A., Soriano, E., Lozach, O., Meijer, L., & Marco, J. L. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.06.099 · Cited by 98
Self-citationHow Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?
Jorda, R., Hendrychová, D., Voller, J., Řezníčková, E., Gucký, T., & Kryštof, V. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00049 · Cited by 97
Casein kinases as potential therapeutic targets
Cozza, G., & Pinna, L. A. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1091883 · Cited by 105
Mazumder, K., Aktar, A., Roy, P., Biswas, B., Hossain, M. E., Sarkar, K. K., Bachar, S. C., Ahmed, F., Monjur-Al-Hossain, A. S. M., & Fukase, K. (2022) · Molecules · doi:10.3390/molecules27093036 · Cited by 106
Bibian, M., Rahaim, R. J. J., Choi, J. Y., Noguchi, Y., Schürer, S. C., Chen, W., Nakanishi, S., Licht, K., Rosenberg, L. H., Li, L., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.075 · Cited by 97
Bettayeb, K., Baunbæk, D., Delehouzé, C., Loaëc, N., Hole, A. J., Baumli, S., Endicott, J., Douc‐Rasy, S., Bénard, J., Oumata, N., et al. (2010) · Genes & Cancer · doi:10.1177/1947601910369817 · Cited by 98
Self-citationJorda, R., Havlíček, L., McNae, I. W., Walkinshaw, M. D., Voller, J., Šturc, A., Navrátilová, J., Kuzma, M., Mistrík, M., Bártek, J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200064p · Cited by 88
Targeting mitochondrial dysfunction in neurodegenerative disease: Part II
Burchell, V. S., Gandhi, S., Deas, E., Wood, N. W., Abramov, A. Y., & Plun-Favreau, H. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728221003730434 · Cited by 82
“Derivatives of roscovitine, a broad-specificity blocker of cyclin-dependent kinases and casein kinase 1, have also been suggested as therapeutics for AD [98].”
BackgroundXu, P., Ianes, C., Gärtner, F., Liu, C., Burster, T., Bakulev, V. A., Rachidi, N., Knippschild, U., & Bischof, J. (2019) · Gene · doi:10.1016/j.gene.2019.144005 · Cited by 87
The application of flow microreactors to the preparation of a family of casein kinase I inhibitors
Venturoni, F., Nikbin, N., Ley, S. V., & Baxendale, I. R. (2010) · Organic & Biomolecular Chemistry · doi:10.1039/b925327k · Cited by 79
Qin, Q., Wang, Z., Huang, X., Tan, M., Zou, B., & Liang, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111751 · Cited by 76
D’Mello, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115911 · Cited by 85
Cellular senescence in the aging brain: A promising target for neurodegenerative diseases
Sahu, M. R., Rani, L., Subba, R., & Mondal, A. C. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111675 · Cited by 75
Amyloid Cascade Hypothesis for the Treatment of Alzheimer’s Disease: Progress and Challenges
Wu, T., Lin, D., Cheng, Y., Jiang, S., Riaz, M. W., Fu, N., Mou, C., Ye, M., & Zheng, Y. (2022) · Aging and disease · doi:10.14336/ad.2022.0412 · Cited by 73
“It was reported that the roscovitine derivative (R)-DRF053 (2) possesses potent and dose-dependent CK1 inhibition with an IC50 value of 14 nM and low cytotoxicity in the SH-SY5Y cell model [48, 49].”
BackgroundCDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells
Delehouzé, C., Godl, K., Loaëc, N., Bruyère, C., Desban, N., Oumata, N., Galons, H., Roumeliotis, T. I., Giannopoulou, E. G., Grenet, J., et al. (2014) · Oncogene · doi:10.1038/onc.2013.513 · Cited by 69
Self-citationCheminformatics Tools for Analyzing and Designing Optimized Small Molecule Collections and Libraries
Moret, N., Clark, N. A., Hafner, M. A., Wang, Y., Lounkine, E., Medvedovic, M., Wang, J., Gray, N. S., Jenkins, J. L., & Sorger, P. K. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2019.02.018 · Cited by 74
“, 2009), while the other compounds in the same cluster are reported to have improved cellular potency and selectivity (Kryštof et al., 2002; Oumata et al., 2008).”
BackgroundShi, Z., Tian, L., Qiang, T., Li, J., Xing, Y. Q., Ren, X., Liu, C., & Liang, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02064 · Cited by 72
Bukanov, N. O., Moreno, S. E., Natoli, T. A., Rogers, K. A., Smith, L. A., Ledbetter, S. R., Oumata, N., Galons, H., Meijer, L., & Ibraghimov‐Beskrovnaya, O. (2012) · Cell Cycle · doi:10.4161/cc.22375 · Cited by 70
Self-citationSynthesis and kinase inhibitory activity of novel substituted indigoids
Beauchard, A., Laborie, H., Rouillard, H., Lozach, O., Ferandin, Y., Guével, R. L., Guguen‐Guillouzo, C., Meijer, L., Besson, T., & Thiéry, V. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.07.051 · Cited by 71
Self-citationDurieu, É., Prina, E., Leclercq, O., Oumata, N., Gaboriaud‐Kolar, N., Vougogiannopoulou, K., Aulner, N., Defontaine, A., No, J. H., Ruchaud, S., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00021-16 · Cited by 65
Self-citationSmall molecule modulators targeting protein kinase CK1 and CK2
Qiao, Y., Chen, T., Yang, H., Chen, Y., Lin, H., Qu, W., Feng, F., Liu, W., Guo, Q., Liu, Z., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111581 · Cited by 57
Sahnoun, S., Messaoudi, S., Brion, J., & Alami, M. (2009) · Organic & Biomolecular Chemistry · doi:10.1039/b912033e · Cited by 56
Potential Enzymatic Targets in Alzheimer’s: A Comprehensive Review
Alam, J., & Sharma, L. K. (2018) · Current Drug Targets · doi:10.2174/1389450119666180820104723 · Cited by 58
Maitra, S., & Vincent, B. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120986 · Cited by 56
Bischof, J., Leban, J. J., Zaja, M., Grothey, A., Radunsky, B., Othersen, O. G., Strobl, S., Vitt, D., & Knippschild, U. (2012) · Amino Acids · doi:10.1007/s00726-012-1234-x · Cited by 62
Zhou, M., Rebholz, H., Brocia, C., Warner-Schmidt, J. L., Fienberg, A. A., Nairn, A. C., Greengard, P., & Flajolet, M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915173107 · Cited by 52
Self-citationShallal, H. M., & Russu, W. A. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.02.057 · Cited by 51
Recent Advances in CDK Inhibitors for Cancer Therapy
Heptinstall, A. B., Adiyasa, I., Cano, C., & Hardcastle, I. R. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0246 · Cited by 56
Solanki, S., Innocenti, P., Mas-Droux, C., Boxall, K. J., Barillari, C., van Montfort, R. L. M., Aherne, G. W., Bayliss, R. W., & Hoelder, S. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1011726 · Cited by 50
A Novel Series of Highly Potent 2,6,9-Trisubstituted Purine Cyclin-Dependent Kinase Inhibitors
Gucký, T., Jorda, R., Zatloukal, M., Bazgier, V., Berka, K., Řezníčková, E., Béreš, T., Strnad, M., & Kryštof, V. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4006884 · Cited by 50
Liu, J., Du, J., Yang, Y., & Wang, Y. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.09.005 · Cited by 46
Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor
Bendjeddou, L. Z., Loaëc, N., Villiers, B., Prina, E., Späth, G. F., Galons, H., Meijer, L., & Oumata, N. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.064 · Cited by 46
Self-citationKassis, P., Brzeszcz, J., Bénéteau, V., Lozach, O., Meijer, L., Guével, R. L., Guguen‐Guillouzo, C., Lewiński, K., Bourg, S., Colliandre, L., et al. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.08.048 · Cited by 45
Self-citationYang, L., Li, G., Yan, H., Sun, Q., Ma, S., Ji, P., Wang, Z.-R., Feng, S., Zou, J., & Yang, S. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.08.007 · Cited by 49
The Molecular Clock and Neurodegenerative Disease: A Stressful Time
Carter, B., Justin, H. S., Gulick, D., & Gamsby, J. J. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.644747 · Cited by 42
Pharmacological relevance of CDK inhibitors in Alzheimer's disease
Malhotra, N., Gupta, R. V., & Kumar, P. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105115 · Cited by 43
Recent advances on CDK inhibitors: An insight by means of in silico methods
Tutone, M., & Almerico, A. M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.067 · Cited by 40
Li, F., Aljahdali, I. A. M., & Ling, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116206 · Cited by 36
Vymětalová, L., Havlíček, L., Šturc, A., Skrášková, Z., Jorda, R., Pospíšil, T., Strnad, M., & Kryštof, V. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.01.011 · Cited by 40
Rubenstein, R., Sharma, D. R., Chang, B., Oumata, N., Cam, M., Vaucelle, L., Lindberg, M. F., Chiu, A., Wısnıewskı, T., Wang, K., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00124 · Cited by 40
Self-citationRichter, J., Bischof, J., Zaja, M., Kohlhof, H., Othersen, O. G., Vitt, D., Alscher, V., Pospiech, I., García-Reyes, B., Berg, S., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500600b · Cited by 38
Tandon, M., Johnson, J. K., Li, Z., Xu, S., Wipf, P., & Wang, Q. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075601 · Cited by 37
Demange, L., Abdellah, F. N., Lozach, O., Ferandin, Y., Gresh, N., Meijer, L., & Galons, H. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.10.141 · Cited by 37
Self-citationCosimo, E., McCaig, A. M., Carter-Brzezinski, L. J. M., Wheadon, H., Leach, M. T., Ster, K. L., Berthou, C., Durieu, É., Oumata, N., Galons, H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2170 · Cited by 35
Self-citationDesign, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors
Wilson, S. C., Atrash, B., Barlow, C., Eccles, S., Fischer, P. M., Hayes, A., Kèlland, L. R., Jackson, W., Jarman, M., Mirza, A. R., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.08.051 · Cited by 39
Elagawany, M., Ibrahim, M. A., Ahmed, H. E. A., El-Etrawy, A.-A. S., Ghiaty, A. H., Abdel‐Samii, Z. K., El‐Feky, S. A., & Bajorath, J. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.02.027 · Cited by 35
Meng, T., Qin, Q., Chen, Z., Zou, H., Wang, K., & Liang, F. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112192 · Cited by 31
Guyot, A.-C., Leuxe, C., Disdier, C., Oumata, N., Costa, N., Roux, G. L., Varela, P. F., Duchon, A., Charbonnier, J., Hérault, Y., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57560-3 · Cited by 35
Self-citationDevelopment of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer
Monastyrskyi, A., Nilchan, N., Quereda, V., Noguchi, Y., Ruiz, C. H., Grant, W. M., Cameron, M. D., Duckett, D. R., & Roush, W. R. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.12.020 · Cited by 37
Practical Synthesis of Roscovitine and CR8
Oumata, N., Ferandin, Y., Meijer, L., & Galons, H. (2009) · Organic Process Research & Development · doi:10.1021/op800284k · Cited by 31
Self-citationSundaram, S. S., Nagaraj, S., Mahoney, H. L., Portugues, A., Li, W., Millsaps, K., Faulkner, J., Yunus, A., Burns, C. I., Bloom, C., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-50197-x · Cited by 32
“We found a significant effect of group (F(3,15) = 5.”
BackgroundUse of ATP analogs to inhibit HIV-1 transcription
Narayanan, A., Sampey, G. C., Duyne, R. V., Guendel, I., Kehn‐Hall, K., Roman, J. A., Currer, R., Galons, H., Oumata, N., Joseph, B., et al. (2012) · Virology · doi:10.1016/j.virol.2012.06.007 · Cited by 29
“3rd generation ATP analog inhibits HIV-1 activated transcription We have previously shown that a set of drugs derived from 2,6,9-trisubstituted cdk inhibitory purines as well as 6-aminomethylenebiaryl analogs of CYC202 can down regulate HIV-1 activity (Carpio et al., 2010; Oumata et al., 2008).”
BackgroundSelf-citationSroka, I. M., Heiß, E. H., Havlı́ček, L., Totzke, F., Aristei, Y., Pechan, P. M., Kubbutat, M. H. G., Strnad, M., & Dirsch, V. M. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.060327 · Cited by 29
Mitochondria-localizing curcumin-cryptolepine Zn(II) complexes and their antitumor activity
Qin, L.-Q., Liang, C.-J., Zhou, Z., Qin, Q., Wei, Z., Tan, M., & Liang, H. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115948 · Cited by 27
Molecular roles of Cdk5 in pain signaling
Utreras, E., Futatsugi, A., Pareek, T. K., & Kulkarni, A. B. (2009) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2009.04.004 · Cited by 29
Inhibition of CDK5 Alleviates the Cardiac Phenotypes in Timothy Syndrome
Song, L., Park, S.-H. E., Isseroff, Y., Morikawa, K., & Yazawa, M. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.05.028 · Cited by 30
“…compounds, it was found that four out of the five positive compounds have been reported to inhibit CDK5 (Bettayeb et al., 2008; Brasca et al., 2010; Meijer et al., 1997; Oumata et al., 2008) (Figures 1B, S2G, and S2H), suggesting that CDK5 could be involved in the molecular mechanisms underlying TS.”
Synthesis and Biological Evaluation of a Selective N- and P/Q-Type Calcium Channel Agonist
Liang, M., Tarr, T. B., Bravo‐Altamirano, K., Valdomir, G., Rensch, G., Swanson, L., DeStefino, N. R., Mazzarisi, C. M., Olszewski, R. A., Wilson, G. M., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml3002083 · Cited by 27
Jorda, R., Havlíček, L., Šturc, A., Tušková, D., Daumová, L., Alam, M. M., Škerlová, J., Nekardová, M., Peřina, M., Pospíšil, T., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00189 · Cited by 27
Small‐molecule inducers of Aβ‐42 peptide production share a common mechanism of action
Bettayeb, K., Oumata, N., Zhang, Y., Luo, W., Bustos, V., Galons, H., Greengard, P., Meijer, L., & Flajolet, M. (2012) · The FASEB Journal · doi:10.1096/fj.12-212985 · Cited by 30
Self-citationCasein Kinase 1δ-dependent Wee1 Protein Degradation
Penas, C., Ramachandran, V., Simanski, S., Lee, C., Madoux, F., Rahaim, R. J. J., Chauhan, R., Barnaby, O. S., Schürer, S. C., Hodder, P., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.547661 · Cited by 32
Nair, N. G., Kudo, W., Smith, M. A., Abrol, R., Goddard, W. A., & Reddy, V. P. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.05.019 · Cited by 25
Yin, X., Gong, W., Zeng, Y., Qiu, H., Liu, L., Hollmann, F., & Chen, B. (2024) · ACS Catalysis · doi:10.1021/acscatal.3c04995 · Cited by 24
Hochard, A., Oumata, N., Bettayeb, K., Gloulou, O., Fant, X., Durieu, É., Buron, N., Porceddu, M., Borgne‐Sanchez, A., Galons, H., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121777 · Cited by 29
Self-citationRecent Advances in the Development of Casein Kinase 1 Inhibitors
Li, S., Dong, Y., & Liu, Z. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200713185413 · Cited by 27
Casein Kinase 1δ Inhibitors as Promising Therapeutic Agents for Neurodegenerative Disorders
Catarzi, D., Varano, F., Vigiani, E., Lambertucci, C., Spinaci, A., Volpini, R., & Colotta, V. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220301115124 · Cited by 25
Facilitating the development of molecular glues: Opportunities from serendipity and rational design
Jiang, W., Jiang, Y., Luo, Y., Qiao, W., & Yang, T. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115950 · Cited by 24
Houzé, S., Hoang, N.-T., Lozach, O., Bras, J. L., Meijer, L., Galons, H., & Demange, L. (2014) · Molecules · doi:10.3390/molecules190915237 · Cited by 21
Self-citationA triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore
Shi, Y. H., Park, J., Lagisetti, C., Zhou, W., Sambucetti, L. C., & Webb, T. R. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.12.056 · Cited by 21
Grieco, I., Bissaro, M., Tiz, D. B., Pérez, D. I., Perez, C., Martínez, A., Redenti, S., Mariotto, E., Bortolozzi, R., Viola, G., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113331 · Cited by 20
Novel Medicinal Chemistry Strategies Targeting CDK5 for Drug Discovery
Tang, W., Lin, C., Yu, Q., Zhang, D., Liu, Y., Zhang, L., Zhou, Z., Zhang, J., & Ouyang, L. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00566 · Cited by 19
Řezníčková, E., Weitensteiner, S. B., Havlíček, L., Jorda, R., Gucký, T., Berka, K., Bazgier, V., Zahler, S., Kryštof, V., & Strnad, M. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12618 · Cited by 19
Seleno-Analogs of Scaffolds Resembling Natural Products a Novel Warhead toward Dual Compounds
Astrain-Redín, N., Talavera, I., Moreno, E., Ramírez, M. J., Martínez‐Sáez, N., Encío, I., Sharma, A. K., Sanmartín, C., & Plano, D. (2023) · Antioxidants · doi:10.3390/antiox12010139 · Cited by 18
Carpio, L., Klase, Z. A., Coley, W., Guendel, I., CHOI, S. E., Duyne, R. V., Narayanan, A., Kehn‐Hall, K., Meijer, L., & Kashanchi, F. (2010) · PubMed Central · Cited by 19
Self-citationNovel 8-arylated purines as inhibitors of glycogen synthase kinase
Ibrahim, N., Mouawad, L., & Legraverend, M. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.04.026 · Cited by 18
Zhang, Q., Hu, X., Wan, G., Wang, J., Li, L., Wu, X., Liu, Z., & Yu, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111728 · Cited by 18
Trova, M. P., Barnes, K. D., Alicea, L., Benanti, T. L., Bielaska, M., Bilotta, J., Bliss, B. I., Duong, T. N., Haydar, S. N., Herr, R. J., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.10.011 · Cited by 17
Squarcialupi, L., Betti, M., Catarzi, D., Varano, F., Falsini, M., Ravani, A., Pasquini, S., Vincenzi, F., Salmaso, V., Sturlese, M., et al. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2016.1247060 · Cited by 16
Spinaci, A., Buccioni, M., Catarzi, D., Cui, C., Colotta, V., Ben, D. D., Cescon, E., Francucci, B., Grieco, I., Lambertucci, C., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16020167 · Cited by 16
Trova, M. P., Barnes, K. D., Barford, C., Benanti, T. L., Bielaska, M., Burry, L., Lehman, J. M., Murphy, C., O'Grady, H. R., Peace, D., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.10.025 · Cited by 15
CK1δ as a potential therapeutic target to treat bladder cancer
Lin, Y., Chen, M.-C., Hsieh, T., Liou, J., & Chen, C. (2020) · Aging · doi:10.18632/aging.102966 · Cited by 16
Adamantane-Substituted Purines and Their β-Cyclodextrin Complexes: Synthesis and Biological Activity
Rouchal, M., Rudolfová, J., Kryštof, V., Vojáčková, V., Čmelík, R., & Vícha, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312675 · Cited by 13
Synthesis and biological evaluation of guanidino analogues of roscovitine
Dolečková, I., Česnek, M., Dračínský, M., Brynda, J., Voller, J., Janeba, Z., & Kryštof, V. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.01.021 · Cited by 13
Tabarrini, O., Desantis, J., & Massari, S. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc.16.3 · Cited by 13
Seerden, J.-P. G., Leusink-Ionescu, G., Woudenberg-Vrenken, T. E., Dros, B., Molema, G., Kamps, J. A. A. M., & Kellogg, R. M. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.05.080 · Cited by 13
Impact of GSK-3β and CK-1δ on Wnt signaling pathway in alzheimer disease: A dual target approach
Sharma, V., Sharma, P. C., Reang, J., Yadav, V., Tonk, R. K., Majeed, J., & Sharma, K. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107378 · Cited by 12
Demange, L., Lozach, O., Ferandin, Y., Hoang, N.-T., Meijer, L., & Galons, H. (2012) · Medicinal Chemistry Research · doi:10.1007/s00044-012-0334-1 · Cited by 11
“Moreover, this molecule is able to prevent, in a dose-dependent manner, the CK1-dependent production of amyloid-b in a cell model (Oumata et al., 2008), and consequently might have applications to prevent the appearance and development of AD’s hallmarks.”
BackgroundMethodInfluentialSelf-citationSynthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors
N'gompaza‐Diarra, J., Bettayeb, K., Gresh, N., Meijer, L., & Oumata, N. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.08.033 · Cited by 11
Self-citationTak‐Tak, L., Barbault, F., Maurel, F., Busca, P., & Merrer, Y. L. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.01.048 · Cited by 13
Metadata
- Authors
- Oumata, N., Bettayeb, K., Ferandin, Y., Demange, L., Lopez-Giral, A., Goddard, M.-L., Myrianthopoulos, V., Mikros, E., Flajolet, M., Greengard, P., Meijer, L., & Galons, H.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Laboratoire de Chimie Organique 2, INSERM U 648, Université Paris-Descartes, 4 avenue de l’Observatoire, 75270 Paris cedex 06, France, CNRS, Protein Phosphorylation & Human Disease Group, Station Biologique, B.P. 74, 29682 Roscoff cedex, Bretagne, France, Department of Pharmacy, University of Athens, GR-15771 Athens, Greece, Laboratory of Molecular & Cellular Neuroscience, The Rockefeller University, 1230 York Avenue, New York, New York 10065-6399
- Corresponding author
- Meijer, Laurent
- Galons, Hervé
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-08-13
- Volume
- 51
- Issue
- 17
- Pages
- 5229-5242
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1989404928
- Semantic Scholar
- 7e66b22e8142658b493b4a260facbc3977df92ba
- Cited by
- 139
- References
- 54
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 8 · 2023: 5 · 2022: 9 · 2021: 5 · 2020: 8 · 2019: 7 · 2018: 5 · 2017: 10 · 2016: 7 · 2015: 5 · 2014: 5 · 2013: 12 · 2012: 12
- FWCI
- 8.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- National Institute on Aging (AG09464, P01AG009464)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- cyclin-dependent kinases, casein kinase 1, Alzheimer's disease, amyloid-beta production, tau hyperphosphorylation, CDK1/cyclin B, CDK5/p25, antiproliferative activity, kinase inhibitors
- MeSH terms
- Roscovitine, Animals, Binding Sites, Cell Line, Humans, Models, Molecular, Purines, Structure-Activity Relationship, Amyloid beta-Peptides, Cyclin-Dependent Kinases, Inhibitory Concentration 50, Casein Kinase I, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.